日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1

胶质母细胞瘤的临床适用连接特征包括肿瘤网络驱动因子 CHI3L1

Ling Hai # ,Dirk C Hoffmann # ,Robin J Wagener ,Daniel D Azorin ,David Hausmann ,Ruifan Xie ,Magnus-Carsten Huppertz ,Julien Hiblot ,Philipp Sievers ,Sophie Heuer ,Jakob Ito ,Gina Cebulla ,Alexandros Kourtesakis ,Leon D Kaulen ,Miriam Ratliff ,Henriette Mandelbaum ,Erik Jung ,Ammar Jabali ,Sandra Horschitz ,Kati J Ernst ,Denise Reibold ,Uwe Warnken ,Varun Venkataramani ,Rainer Will ,Mario L Suvà ,Christel Herold-Mende ,Felix Sahm ,Frank Winkler ,Matthias Schlesner ,Wolfgang Wick ,Tobias Kessler

Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models

在体外模型中利用肿瘤治疗场 (TTFields) 破坏胶质母细胞瘤网络

Steffen Schlieper-Scherf, Nils Hebach, David Hausmann, Daniel D Azorín, Dirk C Hoffmann, Sandra Horschitz, Elena Maier, Phillip Koch, Matthia A Karreman, Nima Etminan, Miriam Ratliff

The maternal microbiome in pregnancy, delivery, and early-stage development of neonatal microbiome after cesarean section: A prospective longitudinal study

妊娠、分娩及剖宫产后新生儿微生物组早期发育过程中母体微生物组的变化:一项前瞻性纵向研究

Foessleitner, Philipp; Pjevac, Petra; Granser, Sonja; Wisgrill, Lukas; Pummer, Lisa; Eckel, Fanny; Seki, David; Berry, David; Hausmann, Bela; Farr, Alex

Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma

患者来源的肿瘤类器官用于指导复发性胶质母细胞瘤的个性化药物治疗

Miriam Ratliff, Hichul Kim, Hao Qi, Minsung Kim, Bosung Ku, Daniel Dominguez Azorin, David Hausmann, Rajiv K Khajuria, Areeba Patel, Elena Maier, Loic Cousin, Arnaud Ogier, Felix Sahm, Nima Etminan, Lukas Bunse, Frank Winkler, Victoria El-Khoury, Michael Platten, Yong-Jun Kwon